Search clinical trials for: Surufatinib Durvalizumab EP/EC

Total 13 results

Beijing Chest Hospital

Not yet recruiting

Surufatinib in Combination of Durvalumab and EP/EC in the Firstly-line Treatment of ES-SCLC

Extensive-stage Small-cell Lung Cancer
Hunan Province Tumor Hospital

Completed

Efficacy Biomarker Investigation on Extensive Stage Small Cell Lung Cancer

Extensive Stage Small Cell Lung Cancer

China
Hunan Province Tumor Hospital

Completed

Tumor Microenvironment Surveillance on Simultaneous Liver Metastases Extensive Stage Small Cell Lung Cancer

Extensive Stage Small Cell Lung Cancer

China
China Medical University, China

Not yet recruiting

Durvalumab Combined With Surufatinib as Maintenance Therapy in Patients With Advanced Biliary Tract Cancer

Biliary Tract Cancer

China
Hebei Medical University Fourth Hospital

Recruiting

Durvalumab Combined With Chemoradiotherapy for Limited Stage Small Cell Lung Cancer (Camel-01)

SCLC, Limited Stage

China
Peking Union Medical College Hospital
Harbin Medical University; The First Affiliated Hospital of Xiamen University

Recruiting

Chidamide Plus Etoposide and Cisplatin/Carboplatin as First-line Treatment for Extrapulmonary Neuroendocrine Carcinoma

Neuroendocrine Tumors | Neuroendocrine Carcinoma

China
Peking University

Recruiting

Safety and Efficacy of FOLFSIM Plus Toripalimab in the Treatment of Advanced or Metastatic Neuroendocrine Carcinoma

Neuroendocrine Carcinoma of the Bladder

China
Trans Tasman Radiation Oncology Group
AstraZeneca

Recruiting

Chemotherapy and Immunotherapy in Extensive-Stage Small-Cell Lung Cancer With Thoracic Radiotherapy (CHEST RT)

Extensive-Stage Small-Cell Lung Cancer

Australia
National Cancer Institute (NCI)
NRG Oncology

Active, not recruiting

Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib Alone

Endometrial Mixed Cell Adenocarcinoma | Endometrial Serous Adenocarcinoma | Endometrial Undifferentiated Carcinoma | Stage IV Uterine Corpus Cancer AJCC v8 | Endometrial Adenocarcinoma | Endometrioid Adenocarcinoma

United States, Canada
National Cancer Institute (NCI)

Not yet recruiting

Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small Cell Lung Cancer

Stage IV Lung Cancer AJCC v8 | Extensive Stage Lung Small Cell Carcinoma
National Cancer Institute (NCI)

Active, not recruiting

Testing the Combination of the Anti-cancer Drugs Copanlisib, Olaparib, and MEDI4736 (Durvalumab) in Patients With Advanced Solid Tumors With Selected Mutations

Advanced Malignant Solid Neoplasm | Unresectable Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm

United States
National Cancer Institute (NCI)

Recruiting

Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, (DURVA+ Study)

Malignant Solid Neoplasm

United States
National Cancer Institute (NCI)
NRG Oncology

Active, not recruiting

Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents

Ovarian Seromucinous Carcinoma | Recurrent Ovarian High Grade Serous Adenocarcinoma | Recurrent Platinum-Resistant Ovarian Carcinoma | Fallopian Tube Mucinous Adenocarcinoma | Recurrent Fallopian Tube Clear Cell Adenocarcinoma | Recurrent Fallopian Tube Endometrioid Adenocarcinoma | Recurrent... and other conditions

United States, Puerto Rico

Search clinical trials for: Surufatinib Durvalizumab EP/EC

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Bosnia & Herzegovina

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations